Strategy when Levin was in charge was to focus on CNS and respiratory and to a lesser degree on oncology and women health and no more big acquisitions. It is still unclear what the strategy of the new CEO, who doesn't really have operating experience in the pharmaceutical industry would be. I just hope Teva under his leadership won't make terrible acquisitions as before.
Market Data 
Markets 
AI
